Table 5 The association between GSTs polymorphisms and clinical outcomes

Goekkurt 2006 [11]

GSTM1: M-: 9/32; M+: 4/18

NR

NR

GSTP1: AA: 7/30; GA+GG: 6/18

GG/(GA+AA): 0.65 (0.43, 1.00)

NR

GSTT1: T-: 8/38; T+: 5/12

NR

NR

Ruzzo 2006 [14]

GSTM1: M-: 36/78; M+: 34/97

NR

NR

GSTP1: AA: 20/87; GA+GG: 50/88

GG/AA: 0.58 (0.43, 0.80)

NR

GSTT1: T-: 6/21; T+: 64/154

GA/AA: 0.54 (0.40, 0.74)

NR

NR

Shim 2010 [17]

GSTM1: M-: 48/124; M+: 29/76

M-/M+: 1.10 (0.80, 1.51)

NR

GSTP1: AA: 46/133

AG/AA: 1.12 (0.79, 1.58)

NR

GA+GG: 31/67

GG/AA: 0.76 (0.33, 1.77)

NR

GSTT1: T-: 40/106; T+: 37/94

T-/T+: 0.77 (0.57, 1.06)

Seo 2009 [21]

GSTM1: M-: 12/49; M+: 6/26

NR

NR

GSTP1: AA: 10/47; GA+GG: 8/28

NR

NR

GSTT1: T-: 8/39; T+: 10/36

NR

NR

Liu 2011 [22]

GSTP1: NR

(GG+AG)/AA: 0.53 (0.36, 0.80)

NR

Ott 2008 [23]

GSTM1: M-: 15/52; M+: 13/60

M-/M+: 1.38 (0.92, 2.08)

NR

GSTP1: AA: 12/55; GA+GG: 21/77

AG/AA: 0.80 (0.55, 1.15)

NR

GSTT1: T-: 5/23; T+: 24/87

GG/AA: 0.95 (0.53, 1.71)

NR

T-/T+: 1.09 (0.69, 1.72)

Li 2010 [24]

GSTP1: AA: 17/44; GA+GG: 29/41

(GG+AG)/AA: 0.44 (0.25, 0.78)

SS

Huang 2009 [26]

GSTM1: NR

M-/M+: 1.425 (0.822, 2.469)

NR

GSTP1: NR

(GG+AG)/AA: 0.471 (0.252, 0.878)

NR

Keam 2008 [30]

GSTP1: AA: 22/44; GA+GG: 10/29

(GG+AG)/AA: 0.621 (0.452, 1.606)

NR

Goekkurt 2009 [31]

GSTM1: M-: 26/72; M+: 26/62

NR

NR

GSTP1: AA: 26/64; GA+GG: 26/69

NR

SS

GSTT1: T-: 5/23; T+: 47/111

T-/T+: 1.94 (1.14, 3.32)

NR

Combined analysis(OR/HR, 95CI%)

GSTM1(OR), M-/M+ Total: 1.16 (0.85, 1.58)

GSTM1(HR), M-/M+ Total: 1.23 (0.98, 1.55)

___

RECIST subgroup: 1.07 (0.66, 1.74)

Asian subgroup: 1.17 (0.89, 1.55)

Others subgroup: 1.23 (0.82, 1.84)

European subgroup: 1.38 (0.92, 2.07)

Asian subgroup: 1.04 (0.62, 1.74)

Palliative subgroup: 1.10 (0.80, 1.51)

European subgroup: 1.24 (0.84, 1.82)

Adjuvant subgroup: 1.42 (0.82, 1.47)

Palliative subgroup: 1.04 (0.73, 1.49)

Neoadjuvant subgroup: 1.38 (0.92, 2.07)

Neoadjuvant subgroup: 1.59 (0.86, 2.92)

GSTP1(HR), (GG+AG)/AA, Total: 0.51 (0.39, 0.67)

GSTP1(OR), (GG+AG)/AA

Palliative subgroup: 0.52 (0.39, 0.70)

Adjuvant subgroup: 0.47 (0.25, 0.88)

Total: 1.63 (0.98, 2.70)

All studies reported the data were Asian.

RECIST subgroup: 1.60 (0.98, 2.60)

GSTP1(HR), GG/AA, Total: 0.66 (0.51, 0.85)

WHO subgroup: 0.53 (0.20, 1.38)

Others subgroup: 2.1 (0.93, 4.74)

Asian subgroup: 0.76 (0.33, 1.76)

Asian subgroup: 1.51 (0.72, 3.16)

European subgroup: 0.65 (0.49, 0.85)

European subgroup: 1.74 (0.77, 3.91)

Palliative subgroup: 0.60 (0.45, 0.80)

Palliative subgroup: 1.67 (0.93, 2.99)

Neoadjuvant subgroup: 0.95 (0.53, 1.71)

Neoadjuvant subgroup: 1.34 (0.60, 3.03)

GSTP1(HR), AG/AA, Total: 0.78 (0.51, 1.20)

GSTT1(OR), T-/T+ Total: 0.67 (0.47, 0.97)

RECIST subgroup: 0.79 (0.49, 1.27)

Asian subgroup: 1.12 (0.79, 1.58)

Others subgroup: 0.53 (0.29, 0.97)

European subgroup: 0.65 (0.44, 0.95)

Asian subgroup: 0.87 (0.52, 1.43)

Palliative subgroup: 0.77 (0.38, 1.58)

European subgroup: 0.51 (0.29, 0.88)

Neoadjuvant subgroup: 0.80 (0.55, 1.16)

Palliative subgroup: 0.67 (0.45, 0.99)

GSTT1(HR), T-/T+ Total: 1.14 (0.68, 1.90)

Neoadjuvant subgroup: 0.73 (0.24, 2.18)

Asian subgroup: 0.77 (0.56, 1.05)

European subgroup: 1.43 (0.81, 2.51)

Palliative subgroup: 1.19 (0.48, 2.94)

Neoadjuvant subgroup: 1.09 (0.69, 1.72)